1. Home
  2. PBMWW vs VRAR Comparison

PBMWW vs VRAR Comparison

Compare PBMWW & VRAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBMWW
  • VRAR
  • Stock Information
  • Founded
  • PBMWW N/A
  • VRAR 2016
  • Country
  • PBMWW Canada
  • VRAR United States
  • Employees
  • PBMWW 10
  • VRAR N/A
  • Industry
  • PBMWW
  • VRAR Retail: Computer Software & Peripheral Equipment
  • Sector
  • PBMWW
  • VRAR Technology
  • Exchange
  • PBMWW Nasdaq
  • VRAR Nasdaq
  • Market Cap
  • PBMWW N/A
  • VRAR N/A
  • IPO Year
  • PBMWW N/A
  • VRAR 2021
  • Fundamental
  • Price
  • PBMWW $0.01
  • VRAR $2.62
  • Analyst Decision
  • PBMWW
  • VRAR Strong Buy
  • Analyst Count
  • PBMWW 0
  • VRAR 1
  • Target Price
  • PBMWW N/A
  • VRAR $2.65
  • AVG Volume (30 Days)
  • PBMWW N/A
  • VRAR 3.2M
  • Earning Date
  • PBMWW N/A
  • VRAR 02-12-2025
  • Dividend Yield
  • PBMWW N/A
  • VRAR N/A
  • EPS Growth
  • PBMWW N/A
  • VRAR N/A
  • EPS
  • PBMWW N/A
  • VRAR N/A
  • Revenue
  • PBMWW N/A
  • VRAR $8,137,688.00
  • Revenue This Year
  • PBMWW N/A
  • VRAR $49.45
  • Revenue Next Year
  • PBMWW N/A
  • VRAR N/A
  • P/E Ratio
  • PBMWW N/A
  • VRAR N/A
  • Revenue Growth
  • PBMWW N/A
  • VRAR N/A
  • 52 Week Low
  • PBMWW N/A
  • VRAR $0.50
  • 52 Week High
  • PBMWW N/A
  • VRAR $1.78
  • Technical
  • Relative Strength Index (RSI)
  • PBMWW N/A
  • VRAR 82.30
  • Support Level
  • PBMWW N/A
  • VRAR $1.05
  • Resistance Level
  • PBMWW N/A
  • VRAR $1.78
  • Average True Range (ATR)
  • PBMWW 0.00
  • VRAR 0.29
  • MACD
  • PBMWW 0.00
  • VRAR 0.13
  • Stochastic Oscillator
  • PBMWW 0.00
  • VRAR 97.12

About PBMWW Psyence Biomedical Ltd. Warrant

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Share on Social Networks: